Affordable Access

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

Authors
  • Cannon, C P
  • McCabe, C H
  • Borzak, S
  • Henry, T D
  • Tischler, M D
  • Mueller, H S
  • Feldman, R
  • Palmeri, S T
  • Ault, K
  • Hamilton, S A
  • Rothman, J M
  • Novotny, W F
  • Braunwald, E
Type
Published Article
Journal
Circulation
Publication Date
Feb 03, 1998
Volume
97
Issue
4
Pages
340–349
Identifiers
PMID: 9468207
Source
Medline
License
Unknown

Abstract

The oral glycoprotein IIb/IIIa antagonist sibrafiban achieved effective, long-term platelet inhibition with a clear dose-response but at the expense of a relatively high incidence of minor bleeding. Oral IIb/IIIa inhibition deserves further study as a new treatment strategy in patients after acute coronary syndromes.

Report this publication

Statistics

Seen <100 times